PLANTATION, Fla., May 22 /PRNewswire-FirstCall/ -- In conjunction with its strategy to seek broader regulatory approvals throughout Europe for Multiferon(R) (multi-subtype, natural human alpha interferon) as a first-line adjuvant treatment of high-risk malignant melanoma, Viragen, Inc. and Viragen International, Inc. today announced that the Companies will exhibit at the 6th International Conference on the Adjuvant Therapy of Malignant Melanoma in Stockholm, Sweden on June 15- 17. Multiferon(R) was approved for sale in Sweden in February of this year for the first-line adjuvant treatment of high-risk malignant melanoma following dacarbazine (DTIC) after surgical removal of tumors.
Event details are as follows:
* 6th Annual International Conference on the Adjuvant Therapy of Malignant Melanoma, June 15-17, 2006, Hotel Rival, Stockholm, Sweden For more information: http://www.congrex.com/melanoma
“The adjuvant treatment of malignant melanoma is inconsistent throughout the EU. In most countries where therapy is approved, the regimens include expensive, difficult-to-tolerate therapies that often offer only marginal improvements in survival rates for high-risk category patients,” stated Orjan Norberg, Managing Director of ViraNative AB, a Viragen International subsidiary that manufactures Multiferon(R) in Umea, Sweden. “We are committed to raising public awareness of the increasing global incidence of melanoma and to make physicians and patients aware that our Multiferon(R) regimen offers a safe and effective treatment option with a significant reduction in total treatment time and cost.”
To view the Swedish Multiferon(R) advertisement, please visit: http://www.viragen.com/images/press/multiferon%20ad%20web.pdf About Viragen, Inc.:
With global operations in the U.S., Scotland and Sweden, Viragen is a biotechnology company engaged in the research, development, manufacture and commercialization of pharmaceutical proteins for the treatment of viral diseases and cancers. Our product portfolio includes: Multiferon(R) (multi- subtype, natural human alpha interferon) targeting a broad range of infectious and malignant diseases; and humanized monoclonal antibodies targeting specific antigens over-expressed on many types of cancers. We are also pioneering the development of Avian Transgenic Technology, with the renowned Roslin Institute, as a revolutionary manufacturing platform for the large-scale, efficient and economical production of human therapeutic proteins and antibodies.
For more information, please visit: http://www.Viragen.com Viragen, Inc. Corporate Contact: Douglas Calder, Director of Communications Phone: (954) 233-8746; Fax: (954) 233-1414 E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that can be identified by such terminology such as “believes,” “expects,” “potential,” “plans,” “suggests,” “may,” “should,” “could,” “intends,” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management’s expectations regarding future research, development and/or commercial results could be affected by, among other things, uncertainties relating to clinical trials and product development; availability of future financing; unexpected regulatory delays or government regulation generally; the Company’s ability to obtain or maintain patent and other proprietary intellectual property protection; and competition in general. Forward-looking statements speak only as to the date they are made. The Company does not undertake to update forward-looking statements to reflect circumstances or events that occur after the date the forward-looking statements are made.
Photo: http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-bAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comViragen, Inc.; Viragen International, Inc.
CONTACT: Douglas Calder, Director of Communications, Viragen, Inc.,+1-954-233-8746, or fax, +1-954-233-1414, or dcalder@viragen.com
